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Abstract
There is emerging evidence that Hepatitis C (HCV) treatment engagement is associ-
ated with change in drug behaviours and reduced drug-related death rates among 
people who inject drugs (PWID). The project aims to investigate whether HCV diag-
nosis and treatment engagement reduces all-cause mortality and drug-related death, 
and whether any effect is dependent on treatment regimen and intensity of engage-
ment with staff. Case-control studies comparing: PWID with active HCV infection 
(PCR positive) to PWID HCV infected but spontaneously resolved (PCR negative); 
PCR-positive patients who engaged with treatment services to nonengagers; and pa-
tients who received interferon vs direct-acting antiviral (DAA) based treatment. No 
differences in risk of all-cause mortality or drug-related death between PCR-negative 
controls and PCR-positive cases were detected. The odds of all-cause mortality was 
12.2 times higher in nonengaging persons compared to treatment engaging cases 
(aOR 12.15, 95% CI 7.03-20.99, P < .001). The odds of a drug-related death were 
5.5 times higher in nonengaging persons compared with treatment engaging cases 
(aOR 5.52, 95% CI 2.67- 11.44, P < .001). No differences in risk of all-cause mortal-
ity or drug-related death between interferon-treated cases and DAA-treated con-
trols were detected. HCV treatment engagement is significantly protective against 
all-cause mortality and drug-related death. This engagement effect is independent 
of treatment regimen, with the introduction of DAA therapies not increasing risk of 
drug-related death, suggesting intensity of HCV therapy provider interaction is not 
an important factor.
K E Y W O R D S
case-control studies, drug-related death, hepatitis C, injecting behaviour, people who inject 
drugs
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1  | INTRODUC TION
Hepatitis C (HCV) is a blood-borne virus and affects up to 1% of 
the Scottish Population.1 Around 90% of those infected with HCV 
acquire the virus through injecting drug use behaviour.2 HCV related 
liver disease is a primary contributor to morbidity and mortality 
among people who inject drugs (PWID).3 HCV is preventable, treat-
able and curable, with research supporting the treatment of active 
injecting drug users for Hepatitis C.4 The efficacy of pan-genotypic 
direct-acting antivirals (DAA) provides an excellent opportunity 
to scale up HCV diagnosis and treatment, ultimately achieving the 
WHO target of HCV elimination by 2030.5,6
There is evidence that HCV care engagement is associated with 
change in behaviours among PWID. Studies have demonstrated the 
positive impact of HCV status notification on reduction in injecting 
behaviour among PWID.7,8 Furthermore, a systematic review high-
lighted the positive impact of HCV treatment on patients’ injecting 
and sharing behaviour.9
The causes of death among PWID are strongly associated 
with active drug use.10 Scotland has observed a twofold increase 
in drug-related deaths between 2008 and 2018, with Tayside ex-
periencing the highest number of drug deaths ever recorded in the 
region in 2018.11,12 It is vital that informed action is urgently under-
taken to reverse this trend.
The introduction of Multidisciplinary Managed Care Networks 
(MCN) in HCV treatment has increased access to services and re-
duced all-cause mortality.13 The associated improvement in access 
into care and HCV treatment may have led to a greater degree of 
engagement with health services and may have had a stabilizing 
effect on drug using behaviour. However, there is concern around 
the potential impact of reduction in intensity of staff contact when 
transitioning from the interferon era to the DAA era of treatment. 
Interferon based treatment required a greater intensity of staff to 
patient engagement due to adverse side effects and long treatment 
duration. Contrastingly, DAA based treatment has minimal side ef-
fects and higher cure rates (in excess of 95%).14 Thus, treatment 
pathways are streamlined and arguably provide less opportunity 
for patients to develop a therapeutic relationship with healthcare 
professionals involved in their care, and therefore reduced opportu-
nities to facilitate change in patients’ drug use behaviour, and lower 
risk of mortality.
The aims were to investigate whether HCV diagnosis and en-
gagement in treatment services reduced all-cause mortality and 
drug-related death, and whether any effect was dependent on 
treatment regimen or intensity of engagement with staff. A series 
of retrospective case-control studies were carried out. Initially, 
comparing PWID with active HCV infection (PCR positive) vs 
PWID who were HCV infected but cured spontaneously (PCR 
negative), to elucidate whether knowledge of HCV infection sta-
tus impacted risk of mortality. Secondly, comparing PCR-positive 
patients who engaged vs did not engage with treatment services 
to assess if outcomes were dependent on engagement. Finally, 
comparing interferon treated patients vs DAA-treated patients, 
exploring the effect of intensity of HCV therapy provider interac-
tion on outcomes.
2  | METHODS
2.1 | Data sources and data linkage
The main data source utilised was the Tayside Hepatitis C Clinical 
Database which records patients tested for Hepatitis C, await-
ing treatment, on treatment, cured and re-infected in Tayside, 
Scotland. Data collected from this database included demo-
graphic information, risk factors, laboratory tests, follow-up and 
treatment outcomes. Patients identified from this database and 
forming our cohort were electronically linked with electronic 
medical records and the Tayside Drug Deaths Database, using 
patients’ Community Health Index (CHI) numbers (unique identi-
fication numbers given to every patient registered with a GP in 
Scotland). Information on patients’ mortality status was obtained 
via electronic medical records. Information regarding confirmed 
drug-related deaths in Tayside was sourced from the Tayside Drug 
Deaths Database which records data on all drug-related deaths 
in Tayside and feeds into national reporting mechanisms through 
NHS Information Services Division and also informs the work of 
the Tayside Drug Death Review Group.
2.2 | Identification of selected cohort
From the Tayside clinical database, a cohort of individuals was identi-
fied whose risk factor for HCV was intravenous drug use. Therefore, 
the definition of PWID in our study is people who have “ever in-
jected” drugs, with no differentiation between recent/active and 
former PWID. Individuals with other risk factors, such as transfusion 
of blood products or maternal transmission were excluded as we 
were specifically investigating the impact of HCV treatment on the 
behaviour of PWID. Individuals with non-Tayside postcodes were 
excluded as drug-related death outcomes would not be registered 
for non-Tayside individuals on the Tayside Drug Deaths Database. 
Individuals co-infected with other blood-borne viruses were ex-
cluded from the selected cohort as these individuals would have 
differing mortality rates and treatment experiences to those only 
infected with HCV. Individuals who were tested or initiated on treat-
ment before January 2008 were excluded as the MCN for HCV care 
in Tayside was introduced in 2008 and this substantially changed the 
care pathways. Lastly, individuals who were tested or initiated treat-
ment after November 2017 were excluded to allow for a minimum of 
one year of follow-up.
For each analysis, cases and controls were defined differently, 
although derived from the same cohort previously described. For 
analysis 1, all individuals who tested HCV antibody positive were 
identified. Cases were defined as PWID with active HCV infection 
(PCR positive), and controls were defined as PWID who were HCV 
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infected but cured spontaneously (PCR negative). For analysis 2, all 
individuals who tested HCV PCR positive were identified. Cases 
were defined as PCR-positive patients who engaged with treatment 
services, and controls were defined as PCR-positive patients who 
did not engage with treatment services. For analysis 3, all individuals 
who were PCR positive and engaged with treatment were identified. 
Cases were defined as pegylated interferon alpha treated patients, 
and controls were defined as DAA-treated patients. For all analyses, 
each case was matched with one control by age group (20-35, 36-51, 
52-67, 68-83, 84+) and sex. Controls from the respective categories 
were randomly selected using an online random number generator.
2.3 | Definition of drug-related death
The definition of a drug-related death is a death where the under-
lying cause is as follows: drug abuse or drug dependence; or drug 
poisoning (intentional or accidental) that involves any substance 
controlled under the Misuse of Drugs Act 1971.11 The National 
Records of Scotland uses the ICD 10 classification system to identify 
cases of drug-related death once a death certificate has been issued.
2.4 | Definitions of predictor variables
2.4.1 | Treatment engagement
“Treatment engagement” was defined as engaging with healthcare 
professionals and commencing treatment. All patients who com-
menced treatment were classified as “treatment engagers”, irrespec-
tive of how many days/weeks of treatment they completed, whether 
they completed their entire course of treatment or not, and the out-
come of their treatment, for example if a sustained viral response 
(SVR) was achieved. Correspondingly, patients who did not com-
mence treatment were classified as “treatment non-engagers”.
2.4.2 | Opioid substitution therapy (OST)
Data were collected on individuals’ OST status around the time of 
testing or treatment. Specifically, for analysis 1 (PCR negative vs 
PCR positive) and analysis 2, (treatment engagers vs nonengagers), 
data were collected on whether individuals were on OST at the time 
of HCV RNA PCR testing, ±6 months. For analysis 3 (interferon vs 
DAA-treated patients), data were collected on whether individuals 
were on OST at the time of treatment commencement, ±6 months.
2.4.3 | Cirrhosis
Data were collected on individuals’ cirrhosis status. Individuals were 
classified as being cirrhotic if their liver stiffness (FibroScan) score 
was 12.5 kPa or above, or their FIB-4 score was 3.25 or above.15
2.4.4 | SVR
Data were collected on individuals’ sustained virologic response 
(SVR) status. SVR was defined as absence of detectable HCV RNA at 
24 weeks after cessation of treatment.
2.5 | Statistical analysis
For analysis 1 (PCR negative vs PCR positive) and analysis 2 (treat-
ment engagers vs nonengagers), follow-up began from first antibody 
positive test. For analysis 3 (interferon vs DAA-treated patients), 
follow-up began from date of treatment commencement. For all 
analyses, survival time was exactly observed or censored at the last 
follow-up date (31st December 2018). All statistical analyses were 
performed using IBM SPSS Statistics 22. Baseline characteristics 
were summarised using descriptive statistics. Inter-correlations be-
tween predictor variables were summarised using Pearson's corre-
lational analyses.
Kaplan-Meier survival analysis was performed to investigate dif-
ferences in the rates of all-cause mortality and drug-related deaths 
between cases and controls. Comparison of survival curves was per-
formed using log-rank tests. Binary logistic regressions were used to 
compare the odds of all-cause mortality and dying of a drug-related 
death among cases with those among controls. We estimated odds 
ratios (ORs) and 95% confidence intervals for all comparisons and 
adjusted all models for the matching variables; age and sex. A num-
ber of other covariates were also included in certain models; SVR, 
OST and cirrhosis.
3  | RESULTS
3.1 | Analysis 1 - PCR positive vs negative
A total of 3431 individuals who tested HCV antibody positive were 
identified. Of these, 386 PCR-negative controls and 918 PCR-
positive cases met the inclusion criteria (see Figure 1) and were ran-
domly matched by age group and sex, leading to 386 PCR-negative 
controls and 386 PCR-positive cases included in the study.
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.4%) and controls (96.1%) were 
under the age of 65 years, and male (57.0%).
During the study's follow-up period, there were 135 deaths out 
of 722 individuals who were antibody positive; 72 (53.3%) deaths 
were in PCR-positive cases, and 63 (46.7%) were in PCR-negative 
controls. Of 135 deaths, 63 were classified as drug-related deaths; 
34 (54.0%) were in cases, and 29 (46.0%) were in controls.
For all-cause mortality, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.425, P =.515. No 
difference in risk of all-cause mortality between PCR-negative con-
trols and PCR-positive cases was detected (aOR 1.18, 95% CI 0.80-
1.73, P = .40), after adjustment for age and sex (see Table 2).
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For drug-related deaths, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.291, P =.590. No 
difference in risk of drug-related death between PCR-negative 
controls and PCR-positive cases was detected (aOR 1.19, 95% 
CI 0.71-2.00, P = .512), after adjustment for age and sex (see 
Table 3).
F I G U R E  1   Selection of PCR-positive 
cases and PCR-negative controls based on 
inclusion/exclusion criteria
3431
Individuals tesng HCV anbody
posive 
Potenal Controls = PCR Negave: 
859
Following exclusion of individuals with 
unknown PCR results (N = 11)
Potenal Cases = PCR Posive: 2499
Following exclusion of individuals with 
unknown PCR results (N = 62)
800
Following exclusion of individuals with 
other risk factors e.g. blood products, 
high prevalence country (N = 59)
2288
Following exclusion of individuals with 
other risk factors e.g. blood products, 
high prevalence country (N = 211)
640
Following exclusion of individuals with 
postcodes out with Tayside (N = 160)
2247
Following exclusion of individuals co-
infected with other BBVs (N = 41)
386 PCR Negave controls 
Following exclusion of individuals 
tested before 2008/tested aer 
November 2017 (N = 254)
1999
Following exclusion of individuals with 
postcodes out with Tayside (N = 248)
918 PCR Posive cases
Following exclusion of individuals 
tested before 2008/tested aer 
November 2017 (N = 1081)
Potenal Controls = PCR Negave: 
870
Potenal Cases = PCR Posive: 2561
TA B L E  1   Baseline characteristics of PCR-positive cases and PCR-negative controls (Analysis 1); Treatment Engaging cases and Treatment 
Non-Engaging controls (Analysis 2); and Interferon-treated cases and DAA-treated controls (Analysis 3)
 
Analysis 1 Analysis 2 Analysis 3
Cases (N = 386)
Controls 
(N = 386) Cases (N = 263)
Controls 
(N = 263) Cases (N = 266)
Controls 
(N = 266)
Age, years 
(mean ± SD)
41.77 ± 10.9 41.56 ± 10.92 42.86 ± 10.64 42.98 ± 11.17 43.20 ± 9.20 43.80 ± 9.09
Age ≥ 65 years 14 (3.6%) 15 (3.9%) 9 (3.4%) 7 (2.7%) 3 (1.1%) 6 (2.3%)
Male 220 (57.0%) 220 (57.0%) 177 (67.3%) 177 (67.3%) 201 (75.6%) 201 (75.6%)
SVR   187 (71.1%) 122 (46.4%) 234 (88.0%) 211 (79.3%)
OST     197 (74.1%) 184 (69.2%)
Cirrhosis     34 (13.9%) 40 (15.5%)
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3.2 | Analysis 2 - PCR-positive treatment engagers 
vs PCR-positive treatment nonengagers
A total of 2499 individuals who tested HCV PCR positive were iden-
tified. Of these, 267 treatment nonengaging controls and 650 treat-
ment engaging cases met the inclusion criteria (see Appendix S1) 
and were randomly matched by age group and sex, leading to 263 
treatment nonengaging controls and 263 treatment engaging cases 
included in the study (successful matching was not possible for four 
controls).
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.6%) and controls (97.3%) were 
under the age of 65 years, and male (67.3%).
During the study's follow-up period, there were 141 deaths out 
of 527 individuals who were PCR positive; 23 (16.3%) deaths were in 
treatment engaging cases, and 118 (83.7%) were in treatment non-
engaging controls. Of 141 deaths, 54 were classified as drug-related 
deaths; 10 (18.5%) were in cases, and 44 (81.5%) were in controls.
For all-cause mortality, the survival distributions for the two 
groups were significantly different, with nonengaging controls at 
a significantly higher risk of all-cause mortality, χ2(2) = 91.395, P = 
<.001 (see Figure 2). The odds of all-cause mortality were 12.2 times 
higher among treatment nonengaging controls, (aOR 12.15, 95% CI 
7.03-20.99, P < .001) compared with treatment engaging cases, after 
adjustment for age, sex and OST (see Table 2).
For drug-related deaths, the survival distributions for the two 
groups were significantly different, with nonengaging controls at a 
significantly higher risk of drug-related death, χ2 (2) = 32.364, P = 
<.001 (see Figure 3). The odds of a drug-related death were 5.5 times 
higher among treatment nonengaging controls, (aOR 5.52, 95% CI 
2.67-11.44, P < .001) compared to treatment engaging cases, after 
adjustment for age, sex and OST (see Table 3).
3.3 | Analysis 3 - Interferon treated vs DAA treated
A total of 1664 PCR-positive individuals who engaged with treat-
ment were identified. Of these, 380 interferon treated cases and 
270 directing acting antiviral-treated controls met the inclusion cri-
teria (see Appendix S1) and were randomly matched by age group 
 B (SE)
95% CI for odds ratio
Lower Odds ratio Upper
Analysis 1
Constant −3.82 (0.42)    
Age 0.05* (0.01) 1.04 1.05 1.07
Sex (Male vs Female) −0.23 (0.20) 0.53 0.79 1.18
PCR status (Negative vs 
Positive)
0.16 (0.20) 0.80 1.18 1.73
R2 (Cox & Snell) = 0.06     
Analysis 2
Constant −6.12* (0.71)    
Age 0.08* (0.01) 1.05 1.08 1.11
Sex (Male vs Female) −0.40 (0.27) 0.40 0.67 1.13
OST (No vs Yes) 0.54* (0.25) 1.05 1.71 2.80
Treatment Engagement 
(engagers vs 
nonengagers)
−2.50* (0.28) 7.03 12.15 20.99
R2 (Cox & Snell) = 0.25     
Analysis 3
Constant −3.16* (1.20)    
Age 0.02 (0.02) 0.98 1.02 1.06
Sex (Male vs Female) −0.85 (0.55) 0.15 0.43 1.27
SVR (No vs Yes) −1.17* (0.39) 0.15 0.31 0.66
OST (No vs Yes) 0.44 (0.45) 0.64 1.46 3.71
Cirrhosis (No vs Yes) 0.82 (0.44) 0.95 2.26 5.39
Treatment Regimen (DAA 
vs IFN)
0.37 (0.37) 0.70 1.45 2.98
R2 (Cox & Snell)= 0.04     
*P < .05. 
TA B L E  2   Summary of logistic 
regression analyses for control variables 
(age, sex, SVR, OST and cirrhosis), PCR 
status (Analysis 1), Treatment Engagement 
(Analysis 2) and Treatment Regimen 
(Analysis 3) predicting all-cause mortality
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and sex, leading to 266 interferon-treated cases and 266 directing 
acting antiviral-treated controls included in the study (successful 
matching was not possible for four controls).
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.6%) and controls (97.3%) were 
under the age of 65 years, and male (67.3%).
During the study's follow-up period, there were 49 deaths out 
of 532 PCR-positive individuals who engaged with treatment; 35 
(71.4%) deaths were in interferon treated cases, and 14 (28.6%) were 
in DAA-treated controls. Of 49 deaths, 28 were classified as drug-re-
lated deaths; 21 (75%) in cases, and seven (25%) in controls.
Differences in length of follow-up time between cases and con-
trols were controlled for by implementing a limit of a maximum fol-
low-up period of 55 months after treatment commencement. This 
time parameter was decided upon as the first recorded date of 
treatment commencement in the DAA control group was 1st June 
2014, with a 55 months of follow-up until the final day of follow-up 
31st December 2018. Accordingly, any deaths occurring after the 
established maximum follow-up period in the interferon case group 
were not included in the subsequent analysis. Consequently, nine of 
the 35 deaths, and three of the 21 drug-related deaths, occurring in 
cases were not included in the analysis.
For all-cause mortality, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.071, P =.789. No dif-
ference in risk of all-cause mortality between DAA-treated controls 
and interferon-treated cases was detected (aOR 1.45, 95% CI 0.70-
2.98, P = .37), after adjustment for age, sex, SVR, OST and cirrhosis 
(see Table 2). Note, 28 individuals were omitted from the regression 
analysis due to missing data on cirrhosis; eight controls and 20 cases.
For drug-related deaths, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.281, P =.596. No dif-
ference in risk of drug-related death between DAA-treated controls and 
interferon-treated cases was detected (aOR 2.06, 95% CI 0.80-5.23, P = 
.13), after adjustment for age, sex, SVR, OST and cirrhosis (see Table 3).
4  | DISCUSSION
The aim of the project was to investigate whether HCV diagno-
sis and engagement with treatment services reduces all-cause 
 B (SE)
95% CI for odds ratio
Lower Odds ratio Upper
Analysis 1
Constant −2.45 (0.57)    
Age 0.00 (0.01) 0.98 1.00 1.03
Sex (Male vs Female) −0.36 (0.28) 0.40 0.70 1.20
PCR status (Negative vs 
Positive)
0.17 (0.26) 0.71 1.19 2.00
R2 (Cox & Snell)= 0.00     
Analysis 2
Constant −3.39* (0.81)    
Age −0.01 (0.02) 0.97 0.97 1.03
Sex (Male vs Female) −0.12 (0.33) 0.47 0.89 1.69
OST (No vs Yes) 0.33 (0.32) 0.74 1.39 2.58
Treatment Engagement 
(engagers vs 
nonengagers)
−1.71* (0.37) 2.67 5.52 11.44
R2 (Cox & Snell)= 0.05     
Analysis 3
Constant −3.13* (1.57)    
Age −0.01 (0.03) 0.94 0.99 1.05
Sex (Male vs Female) −0.70 (0.65) 0.14 0.50 1.77
SVR (No vs Yes) −1.38* (0.46) 0.10 0.25 0.62
OST (No vs Yes) 1.45 (0.77) 0.94 4.05 19.35
Cirrhosis (No vs Yes) 0.10 (0.69) 0.29 1.12 4.30
Treatment Regimen (DAA 
vs IFN)
0.72 (0.48) 0.81 2.06 5.23
R2 (Cox & Snell)= 0.03     
*P < .05. 
TA B L E  3   Summary of logistic 
regression analyses for control variables 
(age, sex, SVR, OST, and cirrhosis), PCR 
status (Analysis 1), Treatment Engagement 
(Analysis 2) and Treatment Regimen 
(Analysis 3) predicting drug-related death
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mortality and drug-related death, and whether any effect is de-
pendent on treatment regimen and intensity of engagement with 
HCV treatment service staff. A series of retrospective case-con-
trol studies were performed. The first compared PWID with ac-
tive HCV infection (PCR positive) vs PWID who had been HCV 
infected but cured spontaneously (PCR negative) to answer the 
question does knowledge of HCV infection status change risk of 
death. The only difference between cases and controls was the 
random biological event of spontaneous HCV cure; the two co-
horts can be presumed to have behaved in the same way up to 
the point of being told their HCV status. Our results suggest that 
awareness of HCV infection status makes no difference to mor-
tality, either all cause or drug related.
PWID with a diagnosis of HCV have an increased risk of mortal-
ity compared with noninfected PWID.16 Recent studies have shown 
that awareness of HCV status can be protective, with a reduction 
in injecting behaviour seen in those who have been notified of their 
status.7,8 It has been posited that this behavioural change may occur 
as a result of treatment engagement by some patients rather than 
due to knowledge of HCV status itself.
F I G U R E  2   Kaplan-Meier survival 
curve for time from first antibody positive 
test to all-cause mortality comparing 
treatment engaging cases and treatment 
nonengaging controls
F I G U R E  3   Kaplan-Meier survival 
curve for time from first antibody positive 
test to drug-related death comparing 
treatment engaging cases and treatment 
nonengaging controls
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In the second analysis, we looked at PCR-positive patients 
who engaged vs did not engage with treatment services to explore 
whether self-selecting engagement behaviour accounts for the per-
ceived difference in mortality. Our findings provide evidence that 
HCV treatment engagement is a significant protective factor against 
both all-cause mortality and drug-related death among PWID, with 
nonengaging PCR-positive individuals having 12 times higher odds 
of all-cause mortality and 5 times higher odds of drug-related death, 
in comparison to PCR-positive treatment engaging persons. These 
findings confirm previous research that engaging in Hepatitis C 
treatment leads to a reduction in all-cause mortality.13 It is import-
ant to note that our cohort was selected from a population that has 
a high testing and diagnosis rate, nearly reaching WHO 2030 targets 
with a large proportion being treated to date, so there is minimal 
selection bias in our cohorts. This highlights the need for greater col-
laboration between specialist substance misuse services and HCV 
treatment services to operate in an integrated structure to tackle the 
observed rising trends in drug-related deaths. It is imperative to en-
sure that all services are equipped with adequate levels of resources 
and staffing to assess, manage and treat both patients’ Hepatitis C 
and problematic drug use successfully. Furthermore, engagement in 
HCV care may provide an opportune time to implement targeted 
interventions to reduce injecting behaviours and promote further 
harm reduction measures.
The final analysis attempted to explore further if there was any 
effect of treatment engagement by comparing the outcomes of in-
tensive interaction with health care in interferon treated patients 
vs DAA-treated patients, who have much shorter and less intense 
engagement. The result clearly shows no difference, suggesting that 
the benefits of treatment engagement are associated with the act 
of engaging with treatment rather than the treatment regime itself. 
It could be argued that patients engaging with HCV treatment ser-
vices are self-selecting individuals who are more willing to engage 
with services in general, and that we have observed a generalised 
engagement effect, rather than a specific HCV treatment effect. 
Additionally, it is not clear if nonengaging behaviour is amendable 
to change or improved prognosis. Future research should focus on 
promotion of HCV care and engagement strategies, highlighting the 
psychological, social and physical health benefits of achieving a cure, 
as well as treatment options.17 This finding highlights the importance 
of inclusive accessibility of HCV treatment for PWID.
This finding also has significant implications for addressing on-
going concern around the change in intensity of staff contact when 
transitioning from the interferon era to the DAA era of treatment. 
In addition, it is important to consider that DAA-treated patients 
are arguably more unstable than interferon treated patients as 
many would have been deemed to be unsuitable for interferon 
therapy due to associated adverse side effects. Indeed, it has 
been hypothesised that DAA-treated patients might have worse 
outcomes than interferon treated patients given the less intensive 
support during therapy. Thus, the fact that we observed no differ-
ence in risk of all-cause mortality or drug-related deaths between 
the two groups is evidence that intensity of staff engagement is 
not an important protective factor. Consequently, current treat-
ment practice does not need to implement an increase in intensity 
of staff contact.
4.1 | Limitations
The predominant limitation of the current study was the retrospec-
tive study design, with substantial limitations in quality of available 
data. Data on a number of meaningful variables were not available. 
For instance, OST data were not attainable for PCR-negative indi-
viduals and therefore could not be included as a predictor variable 
in the regression model in analysis 1. Moreover, available OST data 
indicated whether individuals were on OST at the time of diagnosis, 
but not whether they were on OST at the time of their death, which 
could have given more insights. Data on history of nonfatal over-
doses would also have been advantageous, as previous research has 
demonstrated that nonfatal overdose is classified as a risk factor for 
ensuing fatal overdose in PWID.18 Other unattainable data which 
could have been beneficial were injecting history, injecting status, 
change in injecting behaviours and other significant comorbidities.
Furthermore, data on unmeasured potential confounding vari-
ables which may explain the association between engagement and 
decreased risk of mortality is lacking, with further research needed 
to elucidate the complex reasons that lead to nonengagement.
Another limitation to the current study is the lack of differenti-
ation of individuals in analysis 2 (treatment engagers vs nonengag-
ers). Specifically, engagers were not differentiated by a more specific 
measurement of treatment engagement, for example how many 
weeks of treatment they completed and/or whether they completed 
their full course of treatment. Equivalently, nonengagers were not 
differentiated by the reason for their nonengagement. For instance, 
a minority of patients may have not started treatment due to con-
cerns around treatment contra-indications or age. This is particularly 
relevant for patients treated in the interferon treatment era due to 
higher incidence of associated adverse side effects compared with 
DAA based treatment regimens. Arguably such differentiation may 
provide greater insight into the impact of treatment engagement on 
subsequent risk of death, and whether, for example, completion of 
treatment potentiates the engagement effect.
5  | CONCLUSIONS
In conclusion, a series of case-control studies were conducted to in-
vestigate the impact of HCV diagnosis and engagement in treatment 
services on risk of all-cause mortality and drug-related death among 
PWID. No difference in risk of all-cause mortality or drug-related death 
was observed between PWID with active HCV infection (PCR positive) 
and HCV infected but cured spontaneously (PCR negative). HCV treat-
ment engagement is significantly protective against all-cause mortality 
and drug-related death, with nonengaging PCR-positive individuals 12 
times higher odds of all-cause mortality and five times higher odds of 
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drug-related death, in comparison to PCR-positive treatment engaging 
persons. This engagement effect is independent of treatment regimen, 
with no difference in risk of all-cause mortality or drug-related death 
between interferon treated patients and DAA-treated patients, sug-
gesting intensity of engagement with staff is not an important factor. 
These findings provide further evidence of the importance of HCV di-
agnosis and treatment engagement among PWID, reducing their risk of 
mortality, beyond liver-related outcomes.
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